Introduction to Thyroid Eye Disease
Thyroid eye disease, also known as Graves ophthalmopathy or thyroid-associated orbitopathy, is an autoimmune condition that affects the tissues surrounding the eyes. The immune system mistakenly targets the muscles, fat, and connective tissue within the eye socket, leading to inflammation and swelling that can affect vision and daily comfort. Thyroid eye disease is most commonly associated with Graves disease, an autoimmune disorder that causes the thyroid gland to produce excess hormones, though it can also occur in patients with other forms of autoimmune thyroid dysfunction.
Dry eye disease affects more than 16 million diagnosed adults in the United States, according to the National Eye Institute (2023). Among patients with thyroid eye disease, dry eye symptoms are particularly common. The connection between these two conditions is significant: as the tissues behind the eye swell and push the eyeball forward, the eyelids may no longer close completely during blinking or sleep. This incomplete lid closure increases the exposure of the corneal surface to air, accelerating tear evaporation and leaving the eye vulnerable to dryness, irritation, and potential damage. Eyelid retraction, another hallmark of thyroid eye disease, further compounds this problem by widening the opening between the upper and lower lids. At Washington Eye Institute, the care team recognizes the importance of addressing both the underlying thyroid eye disease and the associated dry eye symptoms to preserve comfort and protect the ocular surface.
The root cause of thyroid eye disease lies in an autoimmune response. Antibodies produced by the immune system bind to receptors on cells within the orbit, triggering an inflammatory cascade. This inflammation causes the eye muscles to thicken and the orbital fat and connective tissue to expand. Over time, the increased volume of tissue within the bony orbit pushes the eyes forward and restricts the movement of the eye muscles. Understanding this autoimmune process is essential for guiding treatment decisions and helping patients anticipate how the disease may progress.
Who Benefits Most from Thyroid Eye Disease Treatment
Patients who have been diagnosed with Graves disease and who begin to notice changes in their eyes are among those who benefit most from evaluation and treatment. Eye involvement can develop before, during, or after the onset of thyroid dysfunction, so any new eye symptoms in a patient with a history of autoimmune thyroid disease should prompt a thorough ophthalmic assessment. Early recognition allows the care team to intervene during the active inflammatory phase, when treatment may help limit the extent of tissue changes within the orbit.
Those who develop persistent dryness, grittiness, tearing, or a foreign body sensation as a result of thyroid eye disease can benefit from targeted dry eye management. Because the dryness often stems from increased corneal exposure rather than a deficiency in tear production, treatment strategies may differ from those used for other forms of dry eye. A thorough evaluation helps determine the factors contributing to each patient's symptoms.
Individuals whose thyroid eye disease is causing significant bulging of the eyes, double vision, eyelid retraction, eye pain, or changes in vision require prompt and coordinated care. These symptoms can affect quality of life, make routine tasks such as reading and driving more difficult, and in some cases pose a risk to long-term visual function. Timely treatment is especially important for patients who experience any decrease in color vision or visual acuity, as these signs may indicate compression of the optic nerve.
Because thyroid eye disease involves both the endocrine system and the eyes, patients benefit from a multidisciplinary approach. Those who are managing their thyroid condition with an endocrinologist and who also need ophthalmic care can find value in a practice that understands the interplay between thyroid function and orbital health. Coordination between specialties helps ensure that treatment of one aspect of the disease does not inadvertently worsen another.
Who Is a Good Candidate for Thyroid Eye Disease Evaluation
Any patient with a diagnosis of Graves disease, Hashimoto thyroiditis, or another autoimmune thyroid condition should be aware of the possibility of eye involvement. Even if eye symptoms have not yet appeared, a baseline ophthalmic evaluation can establish a reference point for future comparison. Candidates for ongoing monitoring include those with fluctuating thyroid levels, those who have recently undergone treatment for hyperthyroidism, and those with a family history of autoimmune eye or thyroid disease.
Individuals who notice that their eyes appear more prominent, that their eyelids seem to have pulled back, or that they are experiencing new dry eye symptoms should seek evaluation. Other signs that warrant assessment include puffiness around the eyes, redness of the conjunctiva, difficulty closing the eyes fully, and a sensation of pressure behind the eyes. These changes may develop gradually or progress over a period of weeks.
Double vision, also called diplopia, is a common symptom that occurs when inflamed and enlarged eye muscles are unable to move the eyes in a coordinated fashion. Patients who begin to see two images, especially when looking in certain directions, should be evaluated promptly. Any decrease in visual clarity, changes in color perception, or difficulty with peripheral vision should also be assessed to rule out optic nerve involvement.
Tobacco use is a well-established risk factor for more severe thyroid eye disease. Patients who smoke are encouraged to discuss cessation strategies as part of their overall treatment plan, as stopping tobacco use can improve outcomes and reduce the likelihood of disease progression. Nonsmoking patients may have a more favorable course, though they still require careful monitoring and appropriate treatment.
How Thyroid Eye Disease Develops and Affects the Eyes
Thyroid eye disease typically progresses through two distinct phases. The active phase is characterized by ongoing immune-mediated inflammation within the orbit. During this stage, patients may experience worsening swelling, redness, pain, and progression of symptoms such as proptosis and double vision. The severity varies widely among patients. Identifying whether the disease is in its active phase is important, as many treatments, particularly anti-inflammatory therapies, are most effective during this window.
After the active phase subsides, the disease transitions into a stable or inactive phase. The inflammation resolves, but some of the changes that occurred, such as muscle fibrosis, fat expansion, and eyelid position changes, may persist. Patients in the inactive phase may continue to experience double vision, eyelid retraction, or dry eye related to structural changes rather than ongoing inflammation. Treatment during this phase is typically focused on surgical rehabilitation and ongoing symptom management.
The inflammation causes the extraocular muscles to swell significantly. As these muscles enlarge, they become stiff and fibrotic, limiting eye movement and leading to misalignment. The orbital fat and connective tissue also expand, contributing to the forward displacement of the eyeball known as proptosis or exophthalmos. This forward displacement stretches the optic nerve and increases the corneal surface exposed to the environment, directly contributing to dry eye symptoms.
One of the most clinically significant consequences of thyroid eye disease, from a dry eye perspective, is the inability to fully close the eyelids. When the eyes protrude forward and the eyelids retract, a gap may remain between the upper and lower lids even when the patient attempts to close their eyes. This gap, known as lagophthalmos, allows the tear film to evaporate rapidly, particularly during sleep. The resulting exposure keratopathy can cause corneal drying, punctate erosions, and in severe cases, corneal ulceration. Addressing this exposure is a central component of dry eye management in thyroid eye disease patients.
In a smaller subset of patients, the enlarged muscles and expanded orbital tissues can compress the optic nerve at the back of the orbit. This condition, known as compressive optic neuropathy, is one of the most serious complications of thyroid eye disease. Symptoms may include decreased visual acuity, reduced color vision, and visual field loss. Prompt recognition and treatment of optic nerve compression are essential to prevent irreversible vision loss.
Treatment Options for Thyroid Eye Disease
For many patients with thyroid eye disease, the first line of treatment for dry eye involves preservative-free artificial tears used throughout the day and lubricating ointments applied at bedtime. These products help maintain moisture on the corneal surface and reduce discomfort from tear evaporation. In cases where exposure is significant, moisture chamber glasses or taping the eyelids during sleep may be recommended. The type and frequency of lubrication are tailored to each patient's exposure level and symptom severity.
During the active phase, medical treatment aims to reduce the immune-mediated inflammation driving tissue changes within the orbit. Corticosteroids, administered orally or intravenously, are a commonly used option to suppress inflammation. Orbital radiation therapy may be considered as an adjunct to corticosteroid treatment. Newer biologic therapies that target specific components of the immune response may also be appropriate for certain patients. The choice of therapy depends on the severity of the disease, the patient's overall health, and the response to initial treatment.
Once the disease has entered the inactive phase and inflammation has stabilized, surgical options may be considered. Orbital decompression surgery removes bone or fat from the orbit to create additional space, allowing the eyes to settle back into a more natural position. Strabismus surgery can realign the eyes and reduce double vision. Eyelid surgery may correct eyelid retraction, improve lid closure, and reduce corneal exposure. These procedures are typically performed in a specific sequence, with decompression first, followed by muscle surgery, and eyelid surgery last.
For patients who experience double vision, prism lenses incorporated into glasses can help align the two images seen by each eye into a single, clear picture. Prism glasses are a nonsurgical option that can be especially useful during the active phase of the disease, when surgical correction of eye alignment is generally deferred until the condition stabilizes. The amount and orientation of the prism are customized based on the patient's specific pattern of double vision.
When dry eye symptoms do not respond adequately to artificial tears alone, additional interventions may be considered. Punctal plugs are small devices inserted into the tear drainage channels to retain tears on the eye surface longer. Intense pulsed light (IPL) therapy, available at Washington Eye Institute, may benefit patients whose dry eye includes meibomian gland dysfunction affecting the oil layer of the tear film. These therapies can be used alongside other treatments to optimize comfort and protect the cornea.
Diagnostic Technology and Evaluation Methods
The evaluation of thyroid eye disease begins with a thorough clinical examination. The ophthalmologist assesses the degree of eye protrusion using an exophthalmometer, which measures how far the eye sits forward in the orbit. Eyelid position, lid closure, and eye movement are carefully documented. The corneal surface is evaluated with specialized dyes and a slit lamp microscope to identify areas of dryness or damage. These baseline measurements are essential for tracking changes over time.
Computed tomography (CT) and magnetic resonance imaging (MRI) of the orbits play an important role in diagnosing and managing thyroid eye disease. These imaging studies allow the care team to visualize the extraocular muscles, assess orbital fat volume, and evaluate the optic nerve for signs of compression. CT scanning is particularly useful for surgical planning, while MRI can help distinguish between active inflammation and fibrotic changes. Imaging may be repeated at intervals to monitor the disease.
A complete evaluation includes blood tests to assess thyroid function and the presence of thyroid-related antibodies. Tests such as thyroid-stimulating hormone (TSH), free thyroxine (T4), and thyroid-stimulating immunoglobulin (TSI) levels help confirm the underlying autoimmune process and guide endocrine management. Coordination between the ophthalmology team and the patient's endocrinologist ensures that thyroid levels are optimized, which can positively impact the course of the eye disease.
Determining whether thyroid eye disease is in its active or inactive phase is a key step in planning treatment. The Clinical Activity Score (CAS) is a standardized tool used to evaluate signs of active inflammation, including spontaneous eye pain, pain with eye movement, eyelid redness and swelling, conjunctival redness, and chemosis. A higher score suggests more active inflammation and may indicate that the patient will respond to anti-inflammatory treatment. Serial assessment of the CAS helps the care team determine when the disease has transitioned to the inactive phase.
What to Expect During Evaluation and Treatment
During the first visit at Washington Eye Institute for suspected thyroid eye disease, patients can expect a comprehensive evaluation that includes a medical history, thyroid status assessment, and a thorough eye examination. The care team will measure eye protrusion, evaluate lid position, test eye movement, and examine the corneal surface. Visual acuity, color vision, and visual fields are tested to screen for optic nerve involvement. Patients should bring relevant medical records, including thyroid function test results, to help guide the evaluation.
Treatment for thyroid eye disease is an ongoing process that unfolds over months and sometimes years. During the active phase, the focus is on managing inflammation, protecting the cornea, and monitoring for optic nerve compression. Patients may need frequent follow-up visits to assess disease activity and adjust treatment. Once the disease stabilizes, the care team can discuss surgical rehabilitation if structural changes are causing persistent symptoms.
Patients with thyroid eye disease-related dry eye play an active role in their own care. At-home strategies include using preservative-free artificial tears on a regular schedule, applying lubricating ointment before bed, using a humidifier in dry environments, wearing wraparound sunglasses to reduce wind exposure, and elevating the head of the bed slightly to reduce overnight swelling. Avoiding fans directed at the face and taking regular breaks during screen use can also help minimize symptoms.
Patients with thyroid eye disease should be aware of symptoms that require prompt evaluation. These include a sudden decrease in vision, a change in color perception, increasing eye pain, new or worsening double vision, or a white spot on the cornea. These signs may indicate optic nerve compression or corneal breakdown. Patients are encouraged to contact their care team at Washington Eye Institute if any of these changes occur between scheduled visits.
Your Journey with Thyroid Eye Disease Care
Effective management of thyroid eye disease requires close collaboration between your ophthalmology team and your endocrinologist. Maintaining stable thyroid hormone levels is important for controlling the eye disease. At Washington Eye Institute, the care team communicates with referring endocrinologists to coordinate treatment. Patients who do not yet have an endocrinologist can be referred to one as part of their care plan.
Even after the active phase has resolved, long-term follow-up is important. The care team monitors for late changes in eye position, lid function, or ocular surface health. Dry eye symptoms may persist after the inflammatory phase subsides and may require ongoing management with lubricating drops, punctal plugs, or other therapies. Periodic imaging and thyroid function testing may be recommended to track disease stability.
Thyroid eye disease can affect not only vision and comfort but also appearance and self-confidence. Changes in the appearance of the eyes may cause emotional distress. Patients are encouraged to discuss these concerns with their care team, who can provide reassurance, connect them with support resources, and help them understand what to expect. Taking an active role in treatment decisions can help patients feel more in control of their care.
Certain lifestyle modifications can support the management of thyroid eye disease and associated dry eye. Avoiding tobacco use is one of the most impactful steps a patient can take, as smoking is associated with more severe disease and a poorer response to treatment. Maintaining a balanced diet, managing stress, and getting adequate sleep may also contribute to overall well-being. Protecting the eyes from environmental irritants and wearing sunglasses outdoors are practical steps patients can incorporate into their daily routine.
Patients and their care team work together to establish treatment goals that are realistic and meaningful. For some patients, the primary goal may be to relieve pain and reduce inflammation during the active phase. For others, the focus may be on improving eye alignment, restoring a more natural eyelid position, or achieving lasting relief from dry eye symptoms. Treatment goals often evolve over time as the disease progresses through its phases. Open communication between patients and their care providers helps ensure that expectations are aligned with what can be achieved at each stage.
Questions and Answers About Thyroid Eye Disease
Thyroid eye disease can cause the eyes to protrude forward and the eyelids to retract. These changes increase the corneal surface exposed to the air, accelerating tear evaporation and leading to symptoms such as burning, stinging, grittiness, and blurred vision. Incomplete eyelid closure during blinking and sleep further compounds the problem. Many patients with thyroid eye disease experience dry eye not because they produce fewer tears, but because their tears evaporate too quickly due to increased exposure. Treating the dry eye component is an important part of overall management.
The active inflammatory phase varies from patient to patient. In many cases, it lasts from one to three years before the disease transitions to a stable, inactive phase. Symptoms may fluctuate during this time, with periods of worsening followed by periods of relative stability. The duration and severity can be influenced by factors such as tobacco use, thyroid hormone levels, and the timing of treatment. Regular monitoring helps the care team identify when the disease has transitioned to the inactive phase, which is an important milestone for planning surgical rehabilitation.
In most cases, the vision changes associated with thyroid eye disease can be managed effectively with appropriate treatment. However, if swollen orbital tissues compress the optic nerve and this is not recognized in a timely manner, there is a risk of lasting visual damage. Corneal exposure from incomplete lid closure can also lead to scarring if not adequately protected. Early detection and consistent follow-up are important for minimizing the risk of visual complications.
Tobacco use is one of the most significant modifiable risk factors for thyroid eye disease. Patients who smoke are more likely to develop eye involvement, and their disease tends to be more severe. Smoking also reduces the effectiveness of certain treatments, including corticosteroids and orbital radiation. Patients who stop smoking may experience improved outcomes. The care team can provide guidance and resources to support smoking cessation as part of the overall management plan.
Surgery is generally considered after the disease has entered the inactive phase and inflammation has been stable for several months. Operating during the active phase carries a higher risk of unpredictable outcomes, as ongoing inflammation can alter the surgical result. Common surgical procedures include orbital decompression to reduce proptosis, strabismus surgery to correct double vision, and eyelid surgery to improve lid position and closure. These are typically performed in a specific sequence. The care team will discuss the appropriate timing and approach based on each patient's situation.
The approach at Washington Eye Institute involves a comprehensive evaluation that considers the full spectrum of the condition, from active inflammation to long-term structural changes. The ophthalmology and optometry team works in coordination with each patient's endocrinologist to optimize thyroid function alongside the management of the eye disease. Dry eye symptoms are addressed with lubricating therapies, environmental modifications, and procedures such as punctal plugs or IPL therapy when appropriate. Patients in the active phase are monitored closely, and treatment plans are adjusted based on clinical findings at each visit. For those who require surgical rehabilitation after the disease stabilizes, the team provides guidance on appropriate timing and sequence of procedures. Patient education and open communication are prioritized throughout the process.